Cisplatin, vindesine, and 96-h continuous infusion of 5-fluorouracil as initial chemotherapy for locally advanced head and neck carcinoma.
Details
Serval ID
serval:BIB_B9590FD95222
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Cisplatin, vindesine, and 96-h continuous infusion of 5-fluorouracil as initial chemotherapy for locally advanced head and neck carcinoma.
Journal
American Journal of Clinical Oncology
ISSN
0277-3732 (Print)
ISSN-L
0277-3732
Publication state
Published
Issued date
04/1991
Peer-reviewed
Oui
Volume
14
Number
2
Pages
162-165
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
The combination of cisplatin (80 mg/m2, i.v., day 1), 96-h infusion of 5-fluorouracil (5-FU) (30 mg/kg/24 h) and vindesine (3 mg/m2 days 1 and 8) was evaluated in 31 patients with histologically proven epidermoid carcinoma of the head and neck. All patients were nonpretreated and had measurable lesions. Three (10%) of the 29 evaluable patients achieved a complete response (CR) and 19 (66%) had partial response (PR) with an overall response rate (CR + PR) of 76%. The major toxicity was leukopenia. Median overall survival was 14.5 months. It is concluded that the combination of cisplatin, 96-h infusion of 5-FU, and vindesine was as effective as other regimens including 5-FU and cisplatin reported in the literature, with a similar toxicity. The low CR rate in this trial is related to the high percentage of T4 N3 disease.
Keywords
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Squamous Cell/drug therapy, Cisplatin/administration & dosage, Cisplatin/adverse effects, Drug Synergism, Female, Fluorouracil/administration & dosage, Fluorouracil/adverse effects, Follow-Up Studies, Head and Neck Neoplasms/drug therapy, Humans, Lymphatic Metastasis, Male, Middle Aged, Remission Induction, Survival Rate, Vindesine/administration & dosage, Vindesine/adverse effects
Pubmed
Web of science
Create date
28/01/2008 9:32
Last modification date
20/08/2019 16:27